A djuvant (postoperative) treatment has markedly reduced rates of death due to breast cancer. 1,2 However, in 15 to 25 percent of breast carcinomas, there is amplification of the HER2/neu (ErbB2) gene, an excess of the HER2 protein in the cancer cells, 3 and a high risk of recurrence. [4] [5] [6] Trastuzumab (Herceptin, Roche) is a humanized monoclonal antibody against the HER2 protein. When administered with chemotherapy, it improves survival in advanced HER2-positive breast cancer. 7, 8 When given concomitantly with paclitaxel or after chemotherapy for 12 months as adjuvant treatment for early HER2-positive breast cancer, trastuzumab reduces the risk of recurrence by approximately 50 percent and the risk of death by approximately 30 percent. 9, 10 In these studies, the principal adverse event attributable to trastuzumab was heart failure, which occurred in 1.7 to 4.1 percent of women treated with the antibody; approximately 10 percent of trastuzumabtreated participants had a substantial decrease in the left ventricular ejection fraction. The risk of cardiac dysfunction with trastuzumab treatment increases with the use of anthracyclines. 7, 11 The long-term outcome of trastuzumab-related heart failure is unknown, although symptoms usually subside with cessation of treatment with trastuzumab and management of the condition. 10 Combining trastuzumab with docetaxel, vinorelbine, cisplatin, carboplatin, or paclitaxel has resulted in the highest pooled response rates to date in the treatment of breast cancer. 12 Data obtained in vitro suggest that such combinations kill breast cancer cells by synergistic effects. 13, 14 In the FinHer (Finland Herceptin) study, we compared docetaxel with vinorelbine, administered with or without trastuzumab, as adjuvant treatment for early breast cancer. In this study, trastuzumab was administered before other cardiotoxic therapies and concomitantly with potentially synergistic chemotherapy for only nine weeks to test the hypothesis that such a schedule would limit cardiotoxicity and maintain efficacy.
Me thods

Study Population
Women eligible for the study were less than 66 years of age, had a World Health Organization performance status of 0 or 1, and had undergone breast surgery with axillary-node dissection or sentinel-node biopsy for invasive breast carcinoma. We required determination of steroid hormonereceptor status and HER2 expression by immunohistochemistry, according to the guidelines of each institution. When HER2 expression was scored 2+ or 3+ (on a scale of 0, 1+, 2+, or 3+), the number of copies of the HER2/neu gene was determined by means of chromogenic in situ hybridization in one of two reference laboratories. 15 Participants were randomly assigned (centrally and with computer-assisted blinding) to a study group within 12 weeks after surgery. Eligible patients had either at least one positive axillary node (regardless of the primary tumor size or its hormone-receptor expression) or a node-negative breast-cancer mass at least 20 mm in diameter and a negative test for progesterone receptors (usually defined as staining of <10 percent of the cancer cells). The staging workup included isotope bone scanning; chest radiography or computed tomography (CT); and CT or ultrasonography of the upper abdomen.
Criteria for exclusion were distant metastases, pregnancy, severe hypertension, and cardiac disease (including cardiac failure of any degree, arrhythmia requiring regular medication, and myocardial infarction within the previous 12 months). Patients were ineligible if they had a serum bilirubin level above the upper limit of normal, an alanine or aspartate aminotransferase level greater than 1.5 times the upper limit of normal, an alkaline phosphatase level above 2.5 times the upper limit of normal, a blood leukocyte count below 3.0×10 9 per milliliter, a neutrophil count below 1.5×10 9 per milliliter, or a platelet count below 120×10 9 per milliliter. An ethics committee at Helsinki University Central Hospital approved the study. Study participants provided written informed consent. Figure 1 shows the design of the trial. Randomization was stratified according to HER2 status (positive vs. negative) and institution in this phase 3, open-label, multicenter trial. Permuted blocks were used to randomly assign all participants to receive three cycles of either docetaxel or vinorelbine. Docetaxel (Taxotere, Sanofi-Aventis) was given at a dose of 100 mg per square meter of body-surface area as a one-hour intravenous infusion on day 1 of each 21-day cycle. Vinorelbine (Navelbine, Pierre Fabre) was administered at a dose of 25 mg per square meter as a 5-to-10-minute intravenous infusion on days 1, 8, and 15 of the 21-day cycles. After the completion of docetaxel or vinorelbine treatment, three cycles of a regimen consisting of intravenous fluorouracil at a dose of 600 mg per square meter, epirubicin at a dose of 60 mg per square meter, and cyclophosphamide at a dose of 600 mg per square meter, each administered on day 1 of a 21-day cycle (FEC), were given. The vinorelbine infusion on day 15 was omitted from the third cycle to allow the initiation of FEC at a full dose without delay. The duration of the chemotherapy regimen was 18 weeks.
Study Design
Women who had verified HER2-positive cancer were randomly assigned to receive or not to receive trastuzumab. Nine trastuzumab infusions were administered at one-week intervals; the first infusion was given on day 1 of the first docetaxel or vinorelbine cycle. The primary end point was recurrence-free survival, defined as the time from the date of randomization to the date of detection (with histologic or cytologic confirmation or with radiologic evidence) of local, distant, or contralateral invasive breast cancer or death, whichever occurred first. Secondary end points included adverse effects, the effect of treatment on the left ventricular ejection fraction, the time to distant recurrence, and overall survival, defined as time from randomization to death from any cause.
Study Procedures
Concomitant Therapy
Patients assigned to docetaxel received six 7.5-mg doses of dexamethasone; the first two were given 12 hours and 1 hour before docetaxel infusion and the rest at 12-hour intervals after infusion. Use of prophylactic antibiotics or granulocyte colony-stimulating factors was not recommended unless one or more episodes of febrile neutropenia or severe infection occurred.
Radiotherapy was given after the completion of chemotherapy according to each institution's guidelines, but it was required after breast-conserving surgery. Tamoxifen at a dose of 20 mg per day was administered to patients with estrogenreceptor-positive or progesterone-receptor-positive tumors; this treatment was to be continued for five years.
Dose Modifications
Chemotherapy doses were reduced by 20 percent in cases of persistent hematologic toxic effects or grade 3 or 4 nonhematologic toxic effects, defined according to the National Cancer Institute Common Toxicity Criteria (version 2.0). When either docetaxel or vinorelbine was discontinued because of adverse effects, the cycles not given were replaced by an equal number of cycles of FEC. Trastuzumab was administered at full doses regardless of blood-cell counts, but infusions were deferred whenever vinorelbine or docetaxel infusions were postponed because of adverse effects.
Evaluations
Adverse effects of therapy were recorded on protocol-specified forms on day 21 of each chemotherapy cycle and 12 and 36 months after chemotherapy. Patients were scheduled for follow-up for a minimum of five years. Mammography was performed at one-to-two-year intervals, but otherwise follow-up was carried out according to each institution's guidelines. In the group of patients assigned to trastuzumab treatment, the left ventricular ejection fraction was measured by either echocardiography or isotope cardiography before chemotherapy, after the last FEC cycle, and 12 and 36 months after chemotherapy.
Statistical Analysis
The study was designed to have a power of 0.80 to detect an increase in five-year recurrence-free survival from 70 percent to 80 percent in the docetaxel-plus-FEC group as compared with the vinorelbine-plus-FEC group (with use of a twosided test at a significance level of 0.05); approximately 150 events were required for this purpose. We estimated that 30 percent of the participants would have breast cancer with HER2/neu amplification and that the study would be able to detect a difference in their five-year recurrence-free survival of 50 percent to 67 percent at a power of 0.80 when approximately 1000 patients were enrolled.
Protocol-defined safety analyses took place in March 2001 , September 2001 , and December 2002 The current protocol specified that safety and early efficacy analyses were to be carried out when the median follow-up time exceeded three years; this point was reached in May 2005. The final analyses will be performed when 150 events have occurred or the median follow-up time exceeds five years. For the primary variable, a P value of less than 0.029 was considered to indicate significance, in order to maintain an overall type 1 error of 0.05 for the interim and final analysis. 17 Frequency tables were analyzed with use of the chi-square test. Survival between groups was compared with use of the Kaplan-Meier life-table method and the Cox proportional-hazards model; the log-rank test was used to confirm the robustness of the analysis. Efficacy analyses were based on the intention-to-treat principle. The effects of treatment, time, the method of assessment, and their interactions with the left ventricular ejection fraction were analyzed in a repeated-measures analysis of covariance (ANCOVA) model; pretreat-ment measurement of the ejection fraction was used as a covariate and the ejection fractions measured later as response variables. All P values are two-sided and were not adjusted for multiple testing.
Dr. Joensuu drafted the study design. The investigators initiated the study, and collected, analyzed, and maintained the data. The sponsor (the Finnish Breast Cancer Group) received grants from Sanofi-Aventis, Pierre Fabre, and Pharmacia; Roche supported the HER2/neu analyses. Trastuzumab was purchased from funds provided in the state budget of Finland; other study drugs were purchased by the participating institutions. The manuscript was drafted by Dr. Joensuu and modified by the coauthors. The authors determined the content of the manuscript and vouch for its accuracy and completeness. 18 were randomly assigned to receive either docetaxel (502 women) or vinorelbine (508). Of these 1010 women, 232 who had an amplified HER2/neu gene were further randomly assigned to receive trastuzumab (116 women) or not to receive it (116). The median follow-up times were 36 and 35 months in the docetaxel and vinorelbine groups, respectively, and 37 and 35 months in the trastuzumab and no-trastuzumab (control) groups, respectively, at the time of analysis (May 19, 2005) . No patient was lost to followup. Two women who did not receive the study treatments because of abnormal results on liverfunction tests were excluded from the safety analyses, and one woman (who had been assigned to the vinorelbine group and had HER2/neu-positive cancer) with overt distant metastases at randomization was excluded from the survival analyses. One woman with HER2/neu amplification did not participate in randomization with respect to trastuzumab, and seven women were ineligible. The baseline characteristics of the groups were balanced, except that larger tumors were more common in the docetaxel group than in the vinorelbine group and axillary nodal metastases tended to be more frequent in the trastuzumab group than in the group that did not receive the antibody (Table 1) .
R esults
Most (84.3 percent) of the cancers with strong (3+) HER2-protein expression on immunohistochemical analysis contained amplified HER2/neu. Of the cancers that stained moderately positively (2+), 26.2 percent contained amplified HER2/neu.
Treatment
In February 2002, an independent study-monitoring committee recommended that the dose of docetaxel be reduced because 36.9 percent of the women treated with this agent had received a diagnosis of neutropenic fever. Therefore, 206 of the 502 patients treated with docetaxel (41.0 percent) received 100 mg per square meter and 296 (59.0 percent) received 80 mg per square meter as the starting dose. Three docetaxel cycles were completed by 472 patients (94.0 percent), and three vinorelbine cycles were completed by 483 patients (95.1 percent). Docetaxel (100 mg per square meter), docetaxel (80 mg per square meter), and vinorelbine were given at the protocol-specified dose in 64.7, 83.9, and 82.4 percent of cycles, respectively. The most common reasons for a reduction in the dose of docetaxel were neutropenia and neutropenic infections, and the most common reason for a reduction in the dose of vinorelbine was neutropenia. The full dose of trastuzumab was administered in 99.1 percent of cycles, and 93.6 and 96.6 percent of the protocol-specified trastuzumab infusions were delivered to women in the docetaxel and vinorelbine groups, respectively.
Three or more FEC cycles were administered to 98.6 and 98.0 percent of the women assigned to docetaxel and vinorelbine, respectively, and 91.2 and 93.1 percent received FEC at the protocolspecified dose. Adjuvant radiotherapy was given to 97.0 and 97.6 percent of the patients, respectively, and tamoxifen to 71.1 and 73.8 percent.
Within the subgroup of women with HER2/neupositive cancer, 54 of the women assigned to receive trastuzumab (46.6 percent) and 58 of those who did not receive trastuzumab (50.0 percent) were in the docetaxel group (P = 0.60). The protocol-specified 100-mg dose of docetaxel was administered in 61.1 percent and 64.4 percent of the cycles in the trastuzumab and control groups, respectively; the protocol-specified 80-mg dose of docetaxel in 83.3 percent and 81.6 percent of the cycles, respectively; the protocol-specified dose of vinorelbine in 80.3 percent and 71.9 percent of the cycles, respectively; and the protocol-specified dose of epirubicin in 94.0 percent and 92.0 percent of the cycles, respectively.
Efficacy
Recurrence of breast cancer or death without re- the vinorelbine group, 0.66; 95 percent confidence interval, 0.38 to 1.17; P = 0.15) (Fig. 2B) .
Of the 115 patients in the trastuzumab group who were included in the analysis of efficacy, 12 had a recurrence of breast cancer or died without recurrence, whereas in the control group (116 patients), there were 27 such cases (hazard ratio for recurrence or death in the trastuzumab group, as compared with the control group, 0.42; 95 percent confidence interval, 0.21 to 0.83; P = 0.01) (Fig. 2C) . The hazard ratio remained similar when adjustment was made according to the type of chemotherapy given (0.41; 95 percent confidence interval, 0.21 to 0.82), center (0.42; 95 percent confidence interval, 0.21 to 0.83), or the number of positive nodes (0.39; 95 percent confidence interval, 0.20 to 0.77). Women who received trastuzumab had fewer distant recurrences of cancer than did women who did not receive the antibody (8 vs. 26; hazard ratio, 0.29; 95 percent confidence interval, 0.13 to 0.64; P = 0.002) (Fig. 3) . In addition, their overall survival tended to be better (6 vs. 14 patients died; hazard ratio for death, 0.41; 95 percent confidence interval, 0.16 to 1.08; P = 0.07) (Fig. 2D ).
Adverse Effects
Docetaxel was more commonly associated with neutropenic fever, stomatitis, alopecia, nail problems, toxic effects on the skin, allergic reactions, neuropathy, and edema than was vinorelbine, which more frequently caused peripheral-vein phlebitis and elevation in the serum aspartate aminotransferase level. After the dose of docetaxel was reduced from 100 mg per square meter to 80 mg per square meter, the frequency of neutropenic fever decreased to 14.9 percent (P<0.001). Trastuzumab did not significantly increase the frequency of adverse events related to vinorelbine or docetaxel (Table 2) .
One patient had cardiac infarction and three had cardiac failure; none of these four patients had received trastuzumab. Left ventricular ejection fractions were preserved in women who received trastuzumab (Table 3) . Trastuzumab-treated women had slightly better ejection fractions than those who did not receive trastuzumab; in an ANCOVA model, the estimated difference 12 months after the completion of chemotherapy was 1.7 percentage points (95 percent confidence interval, −0.1 to 3.5 percentage points; P = 0.06), and at 36 months it was 3.0 percentage points (0.7 to 5.4 percentage points, P = 0.01). In this model, vinorelbine and docetaxel had similar estimated effects on the ejection fraction at both times (P = 0.50). Four women treated with trastuzumab (3.5 percent) and seven who were not (6.0 percent) had one or more measurements of ejection fraction more than 15 percentage points less than the pretreatment value. A decrease by more than 10 percentage points, resulting in an ejection fraction of less than 50 percent, occurred in three patients (none of whom had received trastuzumab).
Discussion
Adjuvant docetaxel, as compared with vinorelbine, improved recurrence-free survival in women with breast cancer. However, docetaxel was more toxic, and the scheduled starting dose was reduced during the study because of adverse effects. less favorable among women with HER2/neu-positive cancer who did not receive trastuzumab than among those with HER2/neu-negative cancer (Fig.  3) . Trastuzumab abrogates much of the adverse effect of HER2/neu amplification on outcome.
The proportion of women with HER2/neupositive disease was 23 percent, and thus only 232 women participated in randomization with respect to trastuzumab. The small size of this subgroup and the short duration of the follow-up are limitations of the study. Nevertheless, the number was large enough to allow detection of a statistically significant difference in recurrencefree survival between treatments. When designing the study, we anticipated that HER2/neu amplification would be associated with frequent relapses 4-6 and that trastuzumab would be effective, according to findings in studies of its use in metastatic disease. 7 The likelihood of detecting a difference was expected to be further improved by the use of in situ hybridization to determine the number of copies of HER2/neu during patient selection and by the concomitant use of potentially synergistic chemotherapy. 13, 14 The optimal duration of adjuvant trastuzumab therapy is not known and may be clarified only in further randomized trials. Our results indicate that a nine-week period of trastuzumab administration is effective in women with HER2/neupositive breast cancer. Regimens in which only a few cycles of trastuzumab are administered concurrently with chemotherapy reduce the number of patient visits and may be more cost-effective than regimens that require administration over a period of 12 to 24 months. 9, 10, 21 In addition, such regimens may result in few cardiac adverse effects.
